IOVANCE BIOTHERAPEUTICS INC's ticker is IOVA and the CUSIP is 462260100. A total of 228 filers reported holding IOVANCE BIOTHERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.35 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $1,929,819 | -3.7% | 274,122 | +31.0% | 0.01% | -12.5% |
| Q3 2022 | $2,004,000 | +23.3% | 209,187 | +42.1% | 0.01% | +33.3% |
| Q2 2022 | $1,625,000 | -40.1% | 147,227 | -9.6% | 0.01% | -33.3% |
| Q1 2022 | $2,713,000 | -4.7% | 162,939 | +9.2% | 0.01% | +12.5% |
| Q4 2021 | $2,847,000 | -10.8% | 149,157 | +15.3% | 0.01% | -20.0% |
| Q3 2021 | $3,190,000 | +33.0% | 129,378 | +40.3% | 0.01% | +25.0% |
| Q2 2021 | $2,399,000 | +9.7% | 92,188 | +33.4% | 0.01% | 0.0% |
| Q1 2021 | $2,187,000 | -34.0% | 69,083 | -3.3% | 0.01% | -33.3% |
| Q4 2020 | $3,316,000 | +29.9% | 71,464 | -7.8% | 0.01% | +20.0% |
| Q3 2020 | $2,553,000 | +35.3% | 77,538 | +12.8% | 0.01% | +25.0% |
| Q2 2020 | $1,887,000 | -37.3% | 68,746 | -31.6% | 0.01% | -46.7% |
| Q1 2020 | $3,011,000 | +8.2% | 100,571 | 0.0% | 0.02% | +50.0% |
| Q4 2019 | $2,784,000 | +59.0% | 100,571 | +4.5% | 0.01% | +42.9% |
| Q3 2019 | $1,751,000 | – | 96,200 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Fairmount Funds Management LLC | 565,890 | $26,257,000 | 9.39% |
| Consonance Capital Management LP | 1,710,803 | $79,381,000 | 7.41% |
| GREAT POINT PARTNERS LLC | 917,427 | $42,569,000 | 6.91% |
| Avoro Capital Advisors LLC | 7,500,000 | $348,000,000 | 5.99% |
| Ghost Tree Capital, LLC | 500,000 | $23,200,000 | 5.17% |
| FRAZIER MANAGEMENT LLC | 1,312,999 | $60,923,000 | 4.69% |
| Perceptive Advisors | 9,166,304 | $425,316,000 | 4.56% |
| Ally Bridge Group (NY) LLC | 360,000 | $16,704,000 | 2.86% |
| Orbimed Advisors | 6,645,100 | $308,333,000 | 2.70% |
| ACUTA CAPITAL PARTNERS, LLC | 164,800 | $7,647,000 | 2.08% |